Pharmaceuticals, Biotechnology and Life Sciences
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab).
2Q19 total revenues of $1,203.3 million, a 15 percent increase over 2Q18 and a 23 percent volume increase 2Q19 GAAP…
ULTOMIRIS has the potential to become the new standard of care forboth complement inhibitor-naïve patients and patients switching fromSOLIRIS (eculizumab) –
Alexion has offered to buy shares in a Stockholm-based biopharmaceutical company Wilson Therapeutics, which develops novel therapies for patients with…
The U.S. Food and Drug Administration has approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.